肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价

2015-05-08 范伟译 MedSci原创

dacomitinib(pan-HER抑制剂)头颈部鳞状细胞癌药代动力学
关注

背景：Dacomitinib是一种不可逆的口服pan-HER酪氨酸激酶抑制剂，其针对复发性/转移性(RM)头颈部鳞状细胞癌(SCCHN)有抗肿瘤活性的功效。Dacomitinib相比于标准治疗晚期头颈部鳞状细胞癌的I期临床试验正在进行中(NCT01737008)。许多头颈部鳞状细胞癌患者需要进行肠内喂养，本研究的目的是通过胃造口术喂食管给药时，dacomitinib的药代动力学PK性质(NCT01

背景：Dacomitinib是一种不可逆的口服pan-HER酪氨酸激酶抑制剂，其针对复发性/转移性(RM)头颈部鳞状细胞癌(SCCHN)有抗肿瘤活性的功效。Dacomitinib相比于标准治疗晚期头颈部鳞状细胞癌的I期临床试验正在进行中(NCT01737008)。许多头颈部鳞状细胞癌患者需要进行肠内喂养，本研究的目的是通过胃造口术喂食管给药时，dacomitinib的药代动力学PK性质(NCT01484847)。胃造口术喂食管GT给药的患者很难招募，这项研究通过在放射治疗期间给予单一剂量的药物，在胃造口术喂食管给药的头颈部鳞状细胞癌患者中使用一个独特的设计，确定PK评价的可行性。

方法：符合条件的病人将单一剂量的碎dacomitinib 45毫克悬浮水中通过胃造口术喂食管给药。在禁食状态所有剂量服药以仰卧位进行。PK曲线的绘制先于剂量(t = 0)，30min，1、2、3、4、6、12、24、48、72、96、144、168、192和216小时后剂量，采用HPLC-MS / MS进行分析。本研究的PK参数(平均[CV %])通过比较那些dacomitinib口服给药使用t检验得到。

结果：6名局部晚期头颈部鳞状细胞癌患者被招募进来。患者的平均年龄是54岁。使用两种不同类型的GT：14 F Cope-环形管(n = 3)，20 F挂钩/盘保留管(n = 3)。PK研究显示t1/2为58 h，Cmax为17 ng/ml，达峰时间为8 h，AUC0-inf 为1185 ng *hr/ml，Vd/F 3310 L以及CL/F 为41 L/hr。

结论：与口服给药完整立即释放(IR)片剂相比，GT施药导致Cmax减少了34%，AUC下降了33-44 % (p < 0.05)(Jänne et al.，Clin Cancer Res 2011)。Dacomitinib以水中悬浮液口服给药时，PK性质上没有这种差异性(Bello et al.，Cancer Chemother Pharm 2013)。这些差异可以归因于dacomitinib的水中悬浮液。GT施药时小分子靶向治疗的口服活性应当注意。这项PK临床试验研究表明，GT 施药的患者使用新颖的设计是可行的。

Chiu JW1, Chan K, Chen EX, Siu LL, Abdul Razak AR.

Pharmacokinetic assessment of dacomitinib (panHER tyrosine kinase inhibitor)

 in patients with locally advanced head and neck squamous cell carcinoma 

(LA SCCHN) following administration through a gastrostomy feeding tube (GT).

Invest New Drugs. 2015 May 5

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2016-04-11 qingting

    #细胞癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-09-22 爆笑小医

    #Drug#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2016-03-12 gracezdd

    #MIT#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2016-03-25 xiangyuzhou971

    #EST#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2016-04-17 tsing_hit

    #drugs#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-11-01 fengyqf

    #药代#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2016-03-31 soongzhihua

    #Dacomitinib#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-07-06 jklm09

    #抑制剂#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-05-10 Smile2680

    #头颈部鳞状细胞癌#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1978411, encodeId=da0019e84110a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 11 05:09:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862232, encodeId=b04d1862232fc, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Sep 22 06:09:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900803, encodeId=4467190080305, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Mar 12 16:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050438, encodeId=a6b82050438b1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Mar 25 22:09:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784745, encodeId=6edf1e8474593, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Apr 17 02:09:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Sun Nov 01 21:09:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752057, encodeId=e70f1e5205780, content=<a href='/topic/show?id=4ffe5658f0' target=_blank style='color:#2F92EE;'>#Dacomitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5658, encryptionId=4ffe5658f0, topicName=Dacomitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=548936445000, createdName=soongzhihua, createdTime=Thu Mar 31 09:09:00 CST 2016, time=2016-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851244, encodeId=4568185124440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jul 06 17:09:00 CST 2015, time=2015-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297672, encodeId=5c6f129e6724e, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:09:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-05-10 zhaojie88

    #药代动力学#

    0

以上为热门评论，梅斯医学App还有更多内容